Risk of Secondary Hematological Malignancies in Patients with Follicular Lymphoma: A Retrospective Analysis of 1045 Patients Treated in the Rituximab Era

ConclusionsThis is a retrospective study from rituximab era. The prognosis of follicular lymphoma is good with the current treatment methods and the risk of secondary hematological malignancy seems to be low. Due to low incidence, it seems, that it is not necessary to avoid chemotherapy in the fear of secondary hematological malignancies. However, multiple lines of treatment are associated with higher risk for secondary hematological malignancies. Therefore, the use of regimens with long remission, like rituximab maintenance, would probably reduce the risk of secondary hematological malignancies.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Prusila, R. E. I., Sorigue, M., Postila, A., Salmi, P., Tanhua, T., Tikkanen, S., Kakko, S., Kuitunen, H., Pollari, M., Nystrand, I., Kuusisto, M., Vasala, K., Jantunen, E., Korkeila, E., Karihtala, P., Turpeenniemi-Hujanen, T., Kuittinen, O. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies Source Type: research